SUBSCRIBE
SUBSCRIBE
News   Business

Zeltia Group Says in Advanced Talks to License Aplidin

October 24, 2008 | 
1 min read
MADRID, Oct 24 (Reuters) -Spanish biotechnology firm Zeltia is in advanced talks to license Aplidin in the United States and the rest of the world, with the exception of Europe, where it will license the drug on its own, the company said on Friday.
Alliances Europe
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Weight loss
Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto
Layoffs
Pfizer’s Cost Cuts Claim 200+ Jobs in Switzerland: Report
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Immunology and inflammation
Novartis Unites With Relation in $1.7B Inflammatory Skin Disease Pact
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Poznan, Poland – October 29, 2020: The Glaxosmithkline headquarters office building in Poznan. LOGO. GaxoSmithKline also called GSK is a British pharmaceutical company.
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
December 8, 2025
 · 
2 min read
 · 
Tristan Manalac